The North America Thrombosis And Hemostasis Biomarkers Market would witness market growth of 4.4% CAGR during the forecast period (2023-2030).
Hemostasis and thrombosis biomarkers are a heterogeneous range of biological molecules, cells, or characteristics from laboratory assays that assess hemostatic processes. Many of these indicators are well-characterized criteria with little logistical and financial costs for therapeutic use. Hemostasis, which means keeping blood inside a broken blood vessel, is a biological process to stop and prevent bleeding, which is the first phase of wound healing. Coagulation is involved in this, which turns blood from a liquid into a gel. A blood clot, or thrombus, forming inside a blood vessel is called thrombosis.
It hinders the circulatory system's ability to function correctly by stopping blood flow. The epidemiology of thrombosis differs depending on whether it occurs in the venous or arterial system, whether it is triggered or not, and whether it is the first or subsequent occurrence.
The high prevalence of lung cancer in the region leads to more pulmonary embolism (PE) cases. According to the CDC, the US had 654,620 men and women with previous lung cancer diagnoses as of January 1, 2022, many of whom were coping with metastatic disease. The advanced average age of diagnosis (71 years) is reflected by the fact that about 80% of these people were 65 or older. Due to the poor survival rate, over half (55%) of lung cancer survivors were diagnosed within the previous five years. Hence, the regional market will have numerous growth opportunities in the coming years because of all these elements.
The US market dominated the North America Thrombosis And Hemostasis Biomarkers Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $1,824.3 million by 2030. The Canada market is poised to grow at a CAGR of 6.7% during (2023 - 2030). Additionally, The Mexico market would witness a CAGR of 5.8% during (2023 - 2030).
Based on Product, the market is segmented into Reagents & Consumables, and Analyzers. Based on Application, the market is segmented into Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), and Disseminated Intravascular Coagulation (DIC) & Others. Based on End-use, the market is segmented into Diagnostic Centers, Hospitals & Clinics, and Academic & Research Institutes and Others. Based on Location, the market is segmented into Clinical Laboratory Tests, and Point-of-Care Tests. Based on Type, the market is segmented into Post-Thrombin (PT), Activated Partial Thromboplastin Time (APTT) Test, D-Dimer, Anti-Thrombin III, Plasminogen & Fibrinogen, Soluble Fibrin, Selectins, Factor VIII, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Worldwide Thrombosis And Hemostasis Biomarkers Market is Projected to reach USD 7.4 Billion by 2030, at a CAGR of 5.6%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche Ltd., Siemens Healthineers AG (Siemens AG), Abbott Laboratories, BioMérieux S.A., Horiba Ltd., QuidelOrtho Corporation, Werfen, S.A., Diazyme Laboratories, Inc. (General Atomics) and BioMedica Diagnostics Inc. (Scotia Investments Family of Companies).
By Product
By Application
By End-Use
By Location
By Type
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
